Krystal Biotech KRYS

HealthcareMarket cap $5B1 connection

Krystal Biotech makes Vyjuvek - the first redosable gene therapy, a topical HSV-1 vector that delivers working LAMB3 gene copies to skin cells in patients with RDEB (recessive dystrophic epidermolysis bullosa), a devastating blistering skin disease. Redosable gene therapy is a breakthrough concept that could apply to many skin and mucosal diseases.

Explore Krystal Biotech on the interactive map Relationship timeline Find a path to another company

Suppliers 1

Companies that sell to Krystal Biotech

AmazonConsumer & Retail · $2.0TKrystal Biotech gene therapy logistics on AWS

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Krystal Biotech's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=KRYS" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Krystal Biotech on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.